Stivarga regorafenib: Phase II data

Top-line data from the double-blind, European Phase II REGOSARC trial in 181 patients with metastatic and/or unresectable STS after failure or intolerance to doxorubicin showed that once-daily 160 mg oral Stivarga for the

Read the full 335 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE